The future of inflammatory bowel disease therapy

Inflammatory Bowel Diseases

Volumn 8, Issue 4, 2002, Pages 301-305

  Van Deventer, S J H ^a   Sachar, David B ^b  

^a ACADEMIC MEDICAL CENTER   (Netherlands)

^b MOUNT SINAI HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBIOTIC AGENT; AUTOANTIBODY; AZATHIOPRINE; CORTICOSTEROID; CYCLOSPORIN; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERLEUKIN 12; INTERLEUKIN 18; MERCAPTOPURINE; METHOTREXATE; TOLL LIKE RECEPTOR 4;

APOPTOSIS; ARTICLE; AUTOLOGOUS BONE MARROW TRANSPLANTATION; CHROMOSOME 16; CLINICAL RESEARCH; CONTROLLED STUDY; CROHN DISEASE; GENE MUTATION; GENETIC ENGINEERING; HUMAN; HUMORAL IMMUNE DEFICIENCY; IMMUNOMODULATION; PATHOGENESIS; PRIORITY JOURNAL; T LYMPHOCYTE; ULCERATIVE COLITIS;

EID: 0036061724     PISSN: 10780998     EISSN: None     Source Type: Journal    
DOI: 10.1097/00054725-200207000-00010     Document Type: Article

References (50)

1. Frequency of glucocorticoid resistance and dependency in Crohn's disease
2. Predicting outcome in severe ulcerative colitis
3. Association between insertion mutation in NOD2 gene and Crohn's disease in German and British populations
4. Association of NOD2 leucine-rich repeat variants with susceptibility to Crohn's disease
5. A frameshift mutation in NOD2 associated with susceptibility to Crohn's disease
6. Nod2, a Nod1/Apaf-1 family member that is restricted to monocytes and activates NF-kappa B
7. The NOD: A signaling module that regulates apoptosis and host defense against pathogens
8. Involvement of receptor-interacting protein 2 in innate and adaptive immune responses
9. Nod1, an Apaf-1-like activator of caspase-9 and nuclear factor-kappa B
10. Defective LPS signaling in C3H/HeJ and C57BL/10ScCr mice: Mutations in Tlr4 gene
11. Genetic and physical mapping of the Lps locus: Identification of the toll-4 receptor as a candidate gene in the critical region
12. In vivo gene repair of point and frameshift mutations directed by chimeric RNA/DNA oligonucleotides and modified single-stranded oligonucleotides
13. Gene repair using chimeric RNA/DNA oligonucleotides
14. Correction of the UDP-glucuronosyltransferase gene defect in the gunn rat model of Crigler-Najjar syndrome type I with a chimeric oligonucleotide
15. Infectious complications the year after autologous bone marrow transplantation or peripheral stem cell transplantation for treatment of breast cancer
16. Stem cells in the aetiopathogenesis and therapy of rheumatic disease
17. Lamina propria T cells in Crohn's disease and other gastrointestinal inflammation show defective CD2 pathway-induced apoptosis
18. Resistance of Crohn's disease T cells to multiple apoptotic signals is associated with a Bcl-2/Bax mucosal imbalance
19. Infliximab induces apoptosis in monocytes from patients with chronic active Crohn's disease by using a caspase-dependent pathway
20. Infliximab treatment induces apoptosis of lamina propria T lymphocytes in Crohn's disease
21. Interleukin-10 induces a long-term antigen-specific anergic state in human CD4+ T cells
22. A CD4+ T-cell subset inhibits antigen-specific T-cell responses and prevents colitis
23. CD4+ T cell down-regulation in human intestinal mucosa: Evidence for intestinal tolerance to luminal bacterial antigens
24. Mechanisms of interleukin-10-mediated immune suppression
25. TGF-beta-producing CD4+ mediastinal lymph node cells obtained from mice tracheally tolerized to ovalbumin (OVA) suppress both Th1- and Th2-induced cutaneous inflammatory responses to OVA by different mechanisms
26. Non-Th2 regulatory T-cell control of Th1 autoimmunity
27. Reciprocal IFN-gamma and TGF-beta responses regulate the occurrence of mucosal inflammation
28. Human CD4(+)CD25(+) cells: A naturally occurring population of regulatory T cells
29. A role for TGF-beta in the generation and expansion of CD4+CD25+ regulatory T cells from human peripheral blood
30. CD4(+)CD25(+) immune regulatory cells are required for induction of tolerance to alloantigen via costimulatory blockade
31. CD25+ CD4+ T cells regulate the expansion of peripheral CD4 T cells through the production of IL-10
32. Therapeutic potential of genetically modified T-Lymphocytes in Crohn's disease
33. Interleukin 12 is expressed and actively released by Crohn's disease intestinal lamina propria mononuclear cells
34. IL-18, a novel immuno-regulatory cytokine, is up-regulated in Crohn's disease: Expression and localization in intestinal mucosal cells
35. IL-5 and TNF-alpha participate in recruitment of eosinophils to intestinal mucosa in ulcerative colitis
36. Disparate CD4+ lamina propria (LP) lymphokine secretion profiles in inflammatory bowel disease. Crohn's disease LP cells manifest increased secretion of IFN-gamma, whereas ulcerative colitis LP cells manifest IL-5
37. A new type of perinuclear anti-neutrophil cytoplasmic antibody (p-ANCA) in active ulcerative colitis but not in Crohn's disease
38. Autoimmune hemolytic anemia in ulcerative colitis, cured by colectomy. Report of a case
39. Simultaneous occurrence of inflammatory bowel disease and thyroid disease
40. The thyroid in ulcerative colitis and Crohn's disease. II. Thyroid enlargement and hyperthyroidism in ulcerative colitis
41. Activation of nuclear factor kappa B inflammatory bowel disease
42. Effects of steroid treatment on activation of nuclear factor kappa B in patients with inflammatory bowel disease
43. Interleukin 8 secretion by colonic crypt cells in vitro: Response to injury suppressed by butyrate and enhanced in inflammatory bowel disease
44. The central role of chemokines (chemotactic cytokines) in the immunopathogenesis of ulcerative colitis and Crohn's disease
45. Decreased expression of Toll-like receptor-4 and MD-2 correlates with intestinal epithelial cell protection against dysregulated proinflammatory gene expression in response to bacterial lipopolysaccharide
46. Toll-like receptor 4 resides in the golgi apparatus and colocalizes with internalized lipopolysaccharide in intestinal epithelial cells
47. Lipid mediator-induced expression of bactericidal/permeability-increasing protein (BPI) in human mucosal epithelia
48. Attenuation of colon inflammation through activators of the retinoid X receptor (RXR)/peroxisome proliferator-activated receptor gamma (PPAR gamma) heterodimer. A basis for new therapeutic strategies
49. A controlled double blind study of azathioprine in the management of Crohn's disease
50. A multicenter trial of 6-mercaptopurine and prednisone in children with newly diagnosed Crohn disease